A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)

Non-small Cell Lung Cancer Clinical Trial

Official title: A Phase 2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR-707) Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Pleural Mesothelioma

Status Active, not recruiting

Clinical Trial Summary

Primary Objective:

-To determine the antitumor activity of SAR444245 in combination with other anticancer therapies.

Secondary Objectives:

• To confirm the dose and to assess the safety profile of SAR444245 when combined with other anticancer therapies.

• To assess other indicators of antitumor activity.

• To assess the pharmacokinetic (PK) profile of SAR444245 when given in combination with pembrolizumab.

• To assess the immunogenicity of SAR444245.

Clinical Trial Description

The duration of the study for an individual patient will start from the signature of the main informed consent and include a screening period of up to 28 days, a treatment period [max 35 cycles {cohorts A1, A2, and B1} = 735 days or until PD {cohort C1}], an end-of-treatment visit at least 30 days following the last administration of study drug (or until the patient receives another anticancer therapy, whichever is earlier), and a follow-up visit 3 months after treatment discontinuation and every 3 months following, until disease progression, or initiation of another antitumor treatment, or death, whichever is earlier ;

Related Conditions & MeSH terms

• Lung Neoplasms
• Mesothelioma
• Mesothelioma, Malignant
• Non-small Cell Lung Cancer
• Pleural Mesothelioma

• NCT number: NCT04914897
• Study type: Interventional
• Source: Sanofi
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: September 23, 2021
• Completion date: January 22, 2025